Literature DB >> 26948990

Serum β-Trace Protein and β2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study.

Meredith C Foster1, Josef Coresh2, Chi-Yuan Hsu3, Dawei Xie4, Andrew S Levey1, Robert G Nelson5, John H Eckfeldt6, Ramachandran S Vasan7, Paul L Kimmel8, Jeffrey Schelling9, Michael Simonson10, James H Sondheimer11, Amanda Hyre Anderson4, Sanjeev Akkina12, Harold I Feldman4, John W Kusek8, Akinlolu O Ojo13, Lesley A Inker14.   

Abstract

BACKGROUND: Serum β-trace protein (BTP) and β2-microglobulin (B2M) are independently associated with end-stage renal disease (ESRD) and mortality in the general population and high-risk groups with diabetes or advanced chronic kidney disease (CKD). Less is known about their associations with outcomes and predictive ability in adults with moderate CKD. STUDY
DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,613 adults from the CRIC (Chronic Renal Insufficiency Cohort) Study (45% women; mean age, 57.9 years; 41.0% non-Hispanic black; 51.9% with diabetes). PREDICTORS: BTP and B2M levels with a reciprocal transformation to reflect their associations with filtration, creatinine-based estimated glomerular filtration rate (eGFRcr), measured GFR, and a 4-marker composite score combining BTP, B2M, creatinine, and cystatin C levels. Predictors were standardized as z scores for comparisons across filtration markers. OUTCOMES: ESRD, all-cause mortality, and new-onset cardiovascular disease.
RESULTS: During a 6-year median follow-up, 755 (21%) participants developed ESRD, 653 died, and 292 developed new-onset cardiovascular disease. BTP, B2M, and the 4-marker composite score were independent predictors of ESRD and all-cause mortality, and B2M and the 4-marker composite score of cardiovascular events, after multivariable adjustment. These associations were stronger than those observed for eGFRcr (P vs eGFRcr≤0.02). The 4-marker composite score led to improvements in C statistic and 2.5-year risk reclassification beyond eGFRcr for all outcomes. LIMITATIONS: Filtration markers measured at one time point; measured GFR available in subset of cohort.
CONCLUSIONS: BTP and B2M levels may contribute additional risk information beyond eGFRcr, and the use of multiple markers may improve risk prediction beyond this well-established marker of kidney function among persons with moderate CKD.
Copyright © 2016 National Kidney Foundation Inc. All rights reserved.

Entities:  

Keywords:  Beta-trace protein (BTP); CKD Biomarkers Consortium; Chronic Renal Insufficiency Cohort (CRIC); cardiovascular events; chronic kidney disease (CKD); end-stage renal disease (ESRD); estimated glomerular filtration rate (eGFR); filtration markers; mortality; renal function; β(2)-microglobulin (B2M)

Mesh:

Substances:

Year:  2016        PMID: 26948990      PMCID: PMC4921300          DOI: 10.1053/j.ajkd.2016.01.015

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  17 in total

1.  Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.

Authors:  Brad C Astor; Tariq Shafi; Ron C Hoogeveen; Kunihiro Matsushita; Christie M Ballantyne; Lesley A Inker; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2012-02-04       Impact factor: 8.860

2.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Authors:  Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

3.  Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.

Authors:  Nrupen A Bhavsar; Lawrence J Appel; John W Kusek; Gabriel Contreras; George Bakris; Josef Coresh; Brad C Astor
Journal:  Am J Kidney Dis       Date:  2011-09-22       Impact factor: 8.860

4.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

5.  Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes.

Authors:  Meredith C Foster; Lesley A Inker; Chi-Yuan Hsu; John H Eckfeldt; Andrew S Levey; Meda E Pavkov; Bryan D Myers; Peter H Bennett; Paul L Kimmel; Ramachandran S Vasan; Josef Coresh; Robert G Nelson
Journal:  Am J Kidney Dis       Date:  2015-03-12       Impact factor: 8.860

6.  Serum β-trace protein and risk of mortality in incident hemodialysis patients.

Authors:  Tariq Shafi; Rulan S Parekh; Bernard G Jaar; Laura C Plantinga; Pooja C Oberai; John H Eckfeldt; Andrew S Levey; Neil R Powe; Josef Coresh
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 8.237

7.  Comparison of serum concentrations of β-trace protein, β2-microglobulin, cystatin C, and creatinine in the US population.

Authors:  Stephen P Juraschek; Josef Coresh; Lesley A Inker; Andrew S Levey; Anna Köttgen; Meredith C Foster; Brad C Astor; John H Eckfeldt; Elizabeth Selvin
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-18       Impact factor: 8.237

8.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

Authors:  James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults.

Authors:  Meredith C Foster; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; John Eckfeldt; Stephen P Juraschek; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2013-03-19       Impact factor: 8.860

View more
  31 in total

1.  Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis.

Authors:  Lesley A Inker; Josef Coresh; Yingying Sang; Chi-Yuan Hsu; Meredith C Foster; John H Eckfeldt; Amy B Karger; Robert G Nelson; Xun Liu; Mark Sarnak; Lawrence J Appel; Morgan Grams; Dawei Xie; Paul L Kimmel; Harold Feldman; Vasan Ramachandran; Andrew S Levey
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-10       Impact factor: 8.237

2.  Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.

Authors:  Abdullah S Al Saleh; M Hasib Sidiqi; Eli Muchtar; Francis K Buadi; Angela Dispenzieri; Rahma Warsame; Martha Q Lacy; David Dingli; Wilson I Gonsalves; Taxiarchis V Kourelis; William J Hogan; Suzanne R Hayman; Prashant Kapoor; Shaji K Kumar; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-15       Impact factor: 5.742

3.  Association between albumin-to-globulin ratio and long-term mortality in patients with chronic kidney disease: a cohort study.

Authors:  Mengru Zeng; Yu Liu; Fuyou Liu; Youming Peng; Lin Sun; Li Xiao
Journal:  Int Urol Nephrol       Date:  2020-05-13       Impact factor: 2.370

4.  Prospective association between β2-microglobulin levels and ischemic stroke risk among women.

Authors:  Pamela M Rist; Monik C Jiménez; Kathryn M Rexrode
Journal:  Neurology       Date:  2017-05-10       Impact factor: 9.910

5.  Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Authors:  M C Foster; D E Weiner; A G Bostom; M A Carpenter; L A Inker; P Jarolim; A A Joseph; J W Kusek; T Pesavento; M A Pfeffer; M Rao; S D Solomon; A S Levey
Journal:  Am J Transplant       Date:  2017-03-30       Impact factor: 8.086

6.  Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD.

Authors:  Xun Liu; Meredith C Foster; Hocine Tighiouart; Amanda H Anderson; Gerald J Beck; Gabriel Contreras; Josef Coresh; John H Eckfeldt; Harold I Feldman; Tom Greene; L Lee Hamm; Jiang He; Edward Horwitz; Julia Lewis; Ana C Ricardo; Haochang Shou; Raymond R Townsend; Matthew R Weir; Lesley A Inker; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

Review 7.  Management of Presumed Acute Kidney Injury during Hypertensive Therapy: Stay Calm and Carry on?

Authors:  Teresa K Chen; Chirag R Parikh
Journal:  Am J Nephrol       Date:  2020-01-15       Impact factor: 3.754

Review 8.  Cardiovascular risk prediction in people with chronic kidney disease.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

Review 9.  The Double-Edged Sword of Beta2-Microglobulin in Antibacterial Properties and Amyloid Fibril-Mediated Cytotoxicity.

Authors:  Shean-Jaw Chiou; Huey-Jiun Ko; Chi-Ching Hwang; Yi-Ren Hong
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

Review 10.  Risk Factors for CKD Progression: Overview of Findings from the CRIC Study.

Authors:  Mary Hannan; Sajid Ansari; Natalie Meza; Amanda H Anderson; Anand Srivastava; Sushrut Waikar; Jeanne Charleston; Matthew R Weir; Jonathan Taliercio; Edward Horwitz; Milda R Saunders; Katherine Wolfrum; Harold I Feldman; James P Lash; Ana C Ricardo
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.